PMC8034787_01
Maximum intensity projection of 18-fluorodeoxyglucose positron emission tomography/computed tomography scan showing abnormal increased tracer uptake in the sinuses, breasts, retrosternal, and sacral region
WJNM-20-109-g001.jpg
PMC8034787_01_WJNM-20-109-g001.jpg
F1
Maximum intensity projection images of 18F-FDG PET/CT showed abnormal increased tracer uptake in the sinuses, breasts, retrosternal, and sacral region [Figure 1].
Positron emission tomography/computed tomography images of head and neck showing fluorodeoxyglucose-avid dural deposit in the high parietal region and ill-defined soft-tissue mass involving bilateral nasal cavity, ethmoid sphenoid, and maxillary sinuses with non-fluorodeoxyglucose-avid soft-tissue deposits in bilateral lacrimal glands
WJNM-20-109-g002.jpg
PMC8034787_01_WJNM-20-109-g002.jpg
F2
An FDG-avid ill-defined soft-tissue mass, measuring 4.5 (AP) x 5.2 (T) x 4.0 (CC) cm, involving the bilateral nasal cavity, ethmoid, sphenoid, and maxillary sinuses with right intraorbital extension, displacing right medial rectus, and posteriorly extending into the nasopharynx with maximum standardized uptake value (SUV) of 9.9, was seen [Figure 2].
Positron emission tomography/computed tomography images showing fluorodeoxyglucose-avid deposits in bilateral breasts and ill-defined soft-tissue thickening in spinal canal at S1 vertebral level extending into 1st left sacral neural foramen
WJNM-20-109-g003.jpg
PMC8034787_01_WJNM-20-109-g003.jpg
F3
Hypermetabolic focal pleural thickening in the bilateral hemithorax and multiple well-defined lobulated homogenously enhancing deposits in the bilateral breasts with SUVmax of 4.5 were noted [Figure 3]. There were associated FDG-avid soft-tissue thickening in the retrosternal region, dural deposit in the high parietal region, and ill-defined soft-tissue thickening in the spinal canal at S1 vertebral level extending into the 1st left sacral neural foramen with SUVmax of 8 [Figure 3].
Immunohistochemistry images showing (a) vimentin positive, (b) myeloperoxidase positive, (c) leukocyte common antigen positive, (d) CD43 positive
WJNM-20-109-g004.jpg
PMC8034787_01_WJNM-20-109-g004.jpg
F4
IHC showed Ki index of 80%-90% and diffuse positivity for vimentin, myeloperoxidase, leukocyte common antigen, CD43, CD34, and C-KIT [Figure 4].